Onconova Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update
Onconova Therapeutics (NASDAQ: ONTX) reported its financial results for 2022, revealing a net loss of $19 million, or $0.91 per share, compared to a net loss of $16.2 million in 2021. The company has cash reserves of $38.8 million, expected to fund operations into Q1 2024. Highlights include advancing narazaciclib's Phase 1 trial to a sixth dose escalation cohort and plans for a Phase 1/2a trial combining narazaciclib with letrozole, slated to enroll patients soon. Additionally, rigosertib's trials in RDEB-associated SCC show promising responses, and further trials are advancing in lung cancer and melanoma. A conference call will discuss these results in detail.
- Narazaciclib's Phase 1 trial reached a new escalation cohort with promising safety findings.
- Rigosertib demonstrated complete response in two participants with RDEB-associated SCC.
- Financial reserves of $38.8 million expected to sustain operations into the first quarter of 2024.
- Net loss increased to $19 million in 2022 from $16.2 million in 2021.
- Research and development expenses rose significantly to $11.4 million, primarily related to narazaciclib.
Conference call and live webcast at 4:30 p.m. ET today
NEWTOWN, Pa., March 16, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced financial results for the twelve months ended December 31, 2022, and provided a business update.
Highlights for the fourth quarter of 2022 and recent weeks include:
- Based upon encouraging safety findings from its ongoing Phase 1 program, Onconova intends to administer narazaciclib orally with a continuous daily dosing schedule in upcoming clinical trials. Results from the Phase 1 solid tumor trial evaluating a continuous daily dosing regimen of narazaciclib showed that the maximum tolerated dose was not reached through the fifth dose escalation cohort. The Phase 1 trial will advance to its sixth dose escalation cohort, which will evaluate a dose of 240 mg orally on a continuous daily schedule.
- The Phase 1/2a trial of narazaciclib combined with letrozole in recurrent metastatic low-grade endometrioid endometrial cancer (LGEEC) is expected to open for enrollment in the first quarter of 2023. The trial remains on track for a preliminary data readout from its Phase 1 portion in the fourth quarter of 2023.
- Two abstracts describing the results of preclinical studies of narazaciclib were recently accepted for poster presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting. The abstracts, which are available on the AACR website, are titled “Differential targets engaged by narazaciclib in comparison to the approved CDK4/6 inhibitors contribute to enhanced inhibition of tumor cell growth” and “Synergistic activity of the CDK4/6 antagonist narazaciclib (ON123300) with irreversible BTK inhibition in ibrutinib-resistant mantle cell lymphoma.”
- The investigator-sponsored Phase 2 program evaluating rigosertib monotherapy in advanced squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa (RDEB-associated SCC) continues to progress and remains open for enrollment. The second of two evaluable participants in the program recently achieved a complete clinical response of all cancerous skin lesions following four treatment cycles of oral rigosertib. The program’s first evaluable participant previously achieved a complete response. Both participants remain on therapy and have maintained their response to therapy to-date. Onconova intends to review the program’s initial data with regulators to gain insight on the optimal regulatory path for rigosertib in RDEB-associated SCC, an ultra-rare and invariably fatal condition.
- Rigosertib’s additional investigator-sponsored trials also continue to progress. The Phase 1/2a trial evaluating rigosertib in combination with nivolumab in KRAS-mutated (KRAS+) non-small cell lung cancer (NSCLC) continues to enroll patients in its dose-expansion cohort, with additional data from the trial expected in the second quarter of 2023. A Phase 2 trial of rigosertib in combination with pembrolizumab in patients with checkpoint inhibitor refractory metastatic melanoma is expected to open for enrollment later this quarter.
- Data from cell-based and in vitro assays characterizing rigosertib’s multi-faceted mechanism of action were recently featured in a poster presentation at the AACR Targeting RAS Conference.
Management Commentary
“We recently received IRB approval at New York University Langone Health for our Phase 1/2a trial of narazaciclib plus letrozole in recurrent LGEEC, which is on track for an important preliminary readout later this year,” said Steven M. Fruchtman, M.D., President and Chief Executive Officer of Onconova. “Prior preclinical data as well as single arm and randomized Phase 2 clinical data provide strong proof-of-concept for narazaciclib’s mechanism of action in LGEEC and demonstrate its potential to overcome the numerous shortcomings of the CDK 4/6 inhibitors that are currently used off-label in combination with letrozole in this indication. We look forward to building on these datasets in our upcoming trial, which we believe will further highlight the advantages of narazaciclib’s differentiated kinase inhibitory profile.”
Dr. Fruchtman continued, “Recent progress in rigosertib’s investigator-sponsored trials was highlighted by data from our RDEB-associated SCC program. With both of the program’s evaluable participants achieving a complete clinical response of all cancerous skin lesions with rigosertib monotherapy, we now intend to engage with regulators to identify the most expeditious path to a potential approval in this ultra-orphan indication. In addition, trials of rigosertib combined with checkpoint inhibition continue to advance, with a Phase 2 study in checkpoint-inhibitor refractory melanoma expected to open for enrollment later this quarter and additional data from a Phase 1/2a trial in KRAS-mutated NSCLC expected next quarter. Looking forward, we expect the continued progress of these investigator-sponsored trials to provide an important source of value to complement our lead narazaciclib program, which remains our primary focus.”
Full Year Financial Results
Cash and cash equivalents as of December 31, 2022, were
Research and development expenses were
General and administrative expenses were
Net loss for 2022 was
Conference Call and Webcast
Onconova will host an investment community conference call beginning at 4:30 p.m. Eastern Time, during which management will discuss financial results for the full year 2022, provide a business update, and answer questions. Interested parties can participate by dialing (800) 715-9871 (domestic callers) or (646) 307-1963 (international callers) and using conference ID 3097517.
A live webcast of the conference call will be available in the Investors & Media section of the Company's website at www.onconova.com. A replay of the webcast will be available on the Onconova website for 90 days following the call.
About Onconova Therapeutics, Inc.
Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.
Onconova’s novel, proprietary multi-kinase inhibitor narazaciclib (formerly ON 123300) is being evaluated in two separate and complementary Phase 1 dose escalation and expansion studies. These trials are currently underway in the United States and China. Based on preclinical and clinical studies of CDK 4/6 inhibitors, Onconova is also planning a combination trial of narazaciclib with estrogen blockade in advanced endometrial cancer, as well as its clinical study in additional indications.
Onconova’s product candidate rigosertib is being studied in multiple investigator-sponsored studies, including a dose-escalation and expansion Phase 1/2a study of oral rigosertib in combination with nivolumab in patients with KRAS+ non-small cell lung cancer, and a Phase 2 program evaluating rigosertib monotherapy in advanced squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa (RDEB-associated SCC).
For more information, please visit www.onconova.com.
Forward Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties. These statements relate to Onconova’s expectations regarding its clinical development and trials, its product candidates, its business and financial position. Onconova has attempted to identify forward-looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," “preliminary,” “encouraging,” "approximately" or other words that convey uncertainty of future events or outcomes. Although Onconova believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including the success and timing of Onconova's clinical trials, investigator-initiated trials and regulatory agency and institutional review board approvals of protocols, Onconova’s collaborations, market conditions and those discussed under the heading "Risk Factors" in Onconova's most recent Annual Report on Form 10-K and quarterly reports on Form 10-Q. Any forward-looking statements contained in this release speak only as of its date. Onconova undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Company Contact:
Mark Guerin
Onconova Therapeutics, Inc.
267-759-3680
ir@onconova.us
https://www.onconova.com/contact/
Investor Contact:
Bruce Mackle
LifeSci Advisors, LLC
646-889-1200
bmackle@lifesciadvisors.com
| ONCONOVA THERAPEUTICS, INC. | ||||||||
| Condensed Consolidated Balance Sheets | ||||||||
| (in thousands) | ||||||||
| December 31, | December 31, | |||||||
| 2022 | 2021 | |||||||
| Assets | (unaudited) | |||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 38,757 | $ | 55,070 | ||||
| Receivables | 29 | 28 | ||||||
| Prepaid expenses and other current assets | 561 | 332 | ||||||
| Total current assets | 39,347 | 55,430 | ||||||
| Property and equipment, net | 24 | 38 | ||||||
| Other non-current assets | 1 | 10 | ||||||
| Total assets | $ | 39,372 | $ | 55,478 | ||||
| Liabilities and stockholders' equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 3,860 | $ | 2,757 | ||||
| Accrued expenses and other current liabilities | 3,960 | 3,132 | ||||||
| Deferred revenue | 226 | 226 | ||||||
| Total current liabilities | 8,046 | 6,115 | ||||||
| Deferred revenue, non-current | 3,017 | 3,243 | ||||||
| Total liabilities | 11,063 | 9,358 | ||||||
| Stockholders' equity: | ||||||||
| Preferred stock | - | - | ||||||
| Common stock | 209 | 209 | ||||||
| Additional paid in capital | 491,816 | 490,644 | ||||||
| Accumulated other comprehensive loss | (33 | ) | (14 | ) | ||||
| Accumulated deficit | (463,683 | ) | (444,719 | ) | ||||
| Total stockholders' equity | 28,309 | 46,120 | ||||||
| Total liabilities and stockholders' equity | $ | 39,372 | $ | 55,478 | ||||
| ONCONOVA THERAPEUTICS, INC. | ||||||||
| Condensed Consolidated Statements of Operations | ||||||||
| (in thousands, except share and per share amounts) | ||||||||
| | ||||||||
| Year Ended December 31, | ||||||||
| 2022 | 2021 | |||||||
| (unaudited) | ||||||||
| Revenue | $ | 226 | $ | 226 | ||||
| Operating expenses: | ||||||||
| General and administrative | 8,447 | 9,425 | ||||||
| Research and development | 11,406 | 7,297 | ||||||
| Total operating expenses | 19,853 | 16,722 | ||||||
| Loss from operations | (19,627 | ) | (16,496 | ) | ||||
| Change in fair value of warrant liability | - | 321 | ||||||
| Other income, net | 663 | 12 | ||||||
| Net loss | (18,964 | ) | (16,163 | ) | ||||
| Net loss per share of common stock, basic and diluted | $ | (0.91 | ) | $ | (0.96 | ) | ||
| Basic and diluted weighted average shares outstanding | 20,908,235 | 16,832,198 | ||||||
FAQ
What were the financial results for Onconova Therapeutics in 2022?
What is the status of narazaciclib's clinical trials at Onconova?
When is the Phase 1/2a trial of narazaciclib with letrozole expected to open?
What progress has been made with rigosertib in clinical trials?
What are Onconova's cash reserves as of December 31, 2022?
